# Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)

> **NCT05224141** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 460 (actual)

## Conditions studied

- Small Cell Lung Carcinoma

## Interventions

- **BIOLOGICAL:** Pembrolizumab/Vibostolimab Co-Formulation
- **DRUG:** Saline placebo
- **DRUG:** Etoposide
- **DRUG:** Cisplatin
- **BIOLOGICAL:** Atezolizumab
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT05224141
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-03-24
- **Primary completion:** 2024-06-04
- **Final completion:** 2027-06-07
- **Target enrollment:** 460 (ACTUAL)
- **Last updated:** 2025-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05224141

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05224141, "Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05224141. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*